PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26265436-6	2015	Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline.	Nortriptyline	294-307	solute carrier family 6 member 4	Homo sapiens	131-152	
26265436-6	2015	Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline.	Nortriptyline	294-307	solute carrier family 6 member 4	Homo sapiens	154-160	
21658141-0	2012	Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation.	Nortriptyline	86-99	solute carrier family 6 member 4	Homo sapiens	24-45	
21658141-1	2012	AIMS: We investigated whether variants in the serotonin transporter gene (SLC6A4) influence smoking cessation rates using antidepressant therapy (i.e. bupropion and nortriptyline).	Nortriptyline	165-178	solute carrier family 6 member 4	Homo sapiens	46-67	
21658141-11	2012	CONCLUSIONS: Bupropion and nortriptyline seem to be more effective in smoking cessation among SLC6A4 high-activity variant carriers, probably by blocking the increased serotonin transporter activity, thereby increasing serotonin levels.	Nortriptyline	27-40	solute carrier family 6 member 4	Homo sapiens	94-100	
21658141-11	2012	CONCLUSIONS: Bupropion and nortriptyline seem to be more effective in smoking cessation among SLC6A4 high-activity variant carriers, probably by blocking the increased serotonin transporter activity, thereby increasing serotonin levels.	Nortriptyline	27-40	solute carrier family 6 member 4	Homo sapiens	168-189	
19567893-4	2009	METHOD: The 5-HTTLPR and 13 additional markers across the serotonin transporter gene were genotyped in 795 adults with moderate-to-severe depression treated with escitalopram or nortriptyline in the Genome Based Therapeutic Drugs for Depression (GENDEP) project.	Nortriptyline	178-191	solute carrier family 6 member 4	Homo sapiens	58-79	
19441667-0	2008	[Association between polymorphisms of ins/del in the 5-HTT gene and T102C in the 5HTR2A gene and the drug response for escitalopram and nortriptyline in depressed patients].	Nortriptyline	136-149	solute carrier family 6 member 4	Homo sapiens	53-58	
19441667-2	2008	The aim of this study was to find a possible association between polymorphisms of ins/del in the 5-HTT gene and T102C in the 5HTR2A gene and drug response for escitalopram and nortriptyline in depressed patients.	Nortriptyline	176-189	solute carrier family 6 member 4	Homo sapiens	97-102	
14604448-0	2003	Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.	Nortriptyline	162-175	solute carrier family 6 member 4	Homo sapiens	68-89	
14604448-3	2003	However, in patients 25 yr or older, the G protein beta3 polymorphisms did not predict antidepressant response, while the s,s genotype of the serotonin transporter was associated with a poorer response to both fluoxetine and nortriptyline.	Nortriptyline	225-238	solute carrier family 6 member 4	Homo sapiens	142-163